NB
naresh bumma
Research areas: Medicine · Hematology · Multiple Myeloma Research and Treatments · Amyloidosis: Diagnosis, Treatment, Outcomes · Chronic Lymphocytic Leukemia Research
0000-0002-0547-7831
Employment
Employment history is unavailable.
Education
Education history is unavailable.
Projects & Funding
Projects & funding information is unavailable.
Publications (136)
- Lenalidomide in the treatment of anti-myelin-associated glycoprotein neuropathy: A phase 1 study to identify the maximum tolerated dose Save
- Addition of daratumumab to lenalidomide, bortezomib, and dexamethasone for transplantation-eligible patients with newly diagnosed multiple myeloma (GRIFFIN): final analysis of an open-label, randomised, phase 2 trial Save
- Comparison of Patient Outcomes With Two Different Formulations of Melphalan as Conditioning Chemotherapy for Autologous Hematopoietic Cell Transplantation in Multiple Myeloma Save
- Deletion 1p at Time of Diagnosis of Multiple Myeloma Portends Inferior Outcomes Save
- Extensive Intracardiac Cement Embolism in a Patient Undergoing Workup for Bone Marrow Transplant Save
- Health-Related Quality of Life (HRQoL) Among Patients with Triple-Class Exposed Relapsed/Refractory Multiple Myeloma (RRMM) Treated with Linvoseltamab in Linker-MM1: Interim Assessment up to 36 Weeks of Treatment Save
- Impact of bortezomib-based versus lenalidomide maintenance therapy on outcomes of patients with high-risk multiple myeloma Save
- Impact of interval progression before autologous stem cell transplant in patients with multiple myeloma Save
- LINKER-MM1 study: Linvoseltamab (REGN5458) in patients with relapsed/refractory multiple myeloma. Save
- Modified carfilzomib dosing is associated with improved treatment responses and longer time on treatment in patients with multiple myeloma Save
- Outcomes after salvage autologous hematopoietic cell transplant for patients with relapsed/refractory multiple myeloma: a single-institution experience Save
- P-044 Evaluation of the efficacy and safety of two different linvoseltamab Phase 2 dose regimens: results from LINKER-MM1 Save
- P-046 Trial in progress: linvoseltamab, a BCMAxCD3 bispecific antibody, in a Phase 1b multi-cohort study of combination regimens for patients with relapsed/refractory multiple myeloma Save
- P-164 Reduction in disease symptoms/impacts after daratumumab, lenalidomide, bortezomib, and dexamethasone treatment for transplant-eligible patients with newly diagnosed multiple myeloma (GRIFFIN study) Save
- P-247 Efficacy and safety of linvoseltamab 200 mg in patients with relapsed/refractory multiple myeloma (RRMM): analysis of the LINKER-MM1 study Save
- Patterns of Response to 200 Mg Linvoseltamab in Patients with Relapsed/Refractory Multiple Myeloma: Longer Follow-Up of the Linker-MM1 Study Save
- Predictive Score for Utilization of Second Autologous Stem Cell Transplantation in Patients with Multiple Myeloma Save
- S197: LINKER-MM1 STUDY: LINVOSELTAMAB (REGN5458) IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA Save
- Stem cell mobilization yields with daratumumab-and lenalidomide-containing quadruplet induction therapy in newly diagnosed multiple myeloma: findings from the MASTER and GRIFFIN trials Save
- Survival outcomes following autologous stem cell transplant with melphalan 140mg/m2 versus 200mg/m2 preparative regimens in patients with multiple myeloma Save